WHAT IS CLAIMED IS:

1. A compound having a structural Formula I,



I

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

A is:  or  ;

E is: O, S or NR^{14};

W is:  , hydrogen, C_1-C_6 alkyl, $(CH_2)_n$-C_3-C_6 cycloalkyl, haloalkyl or acyl;

Q is: $-C(O)OR^6$ or R^{6A};

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is:
a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

R^1 is: hydrogen, wherein when Z is phenyl or naphthyl and R^2 is H , R^1 is not H,

haloalkyl,

C_1-C_6 alkyl,

C_1-C_6 alkyl-C_1-C_6 alkoxy,

C_1-C_6 alkyl-aryl,

C_2-C_6 alkenyl,

C_2-C_6 alkynyl,

$(CH_2)_n$-C_3-C_6 cycloalkyl,

C_1-C_6 alkoxy,

aryl, or

R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{1a} and R^{1b} are each independently:

hydrogen,

C_1-C_6 alkyl, or

R^1 and R^{1a}, R^1 and R^{1b}, R^2 and R^{1a}, R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R^2 is: hydrogen,
haloalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkyl-C_1-C_6 alkoxy,
C_1-C_6 alkyl-aryl,
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy,
aryl, or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl. cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{2a} is: hydrogen, halo or C_1-C_6 alkyl and wherein R^2 and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R^{15};

R^3 is: hydrogen,
halo,
cyano,
haloalkyl,
C_1–C_6 alkyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
(C_1–C_4 alkyl)-heterocyclyl. wherein the heterocyclyl being optionally substituted with oxo,
(C_1–C_4 alkyl)-$NR^7C(O)_nR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

R^4 and R^5 are each independently:

hydrogen,

halo,

C_1-C_6 alkyl

C_1-C_6 alkoxy;

aryloxy;

$N(R^8)_2$,

SR^8 or

R^4 and R^5 together being a 3- to 8-membered ring;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, C_1-C_3 alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R^7 is: hydrogen or C_1-C_6 alkyl;

R^8 and R^9 are each independently:

hydrogen, C_1-C_6 alkyl, aryl, heteroaryl, or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl and C_1-C_6 alkoxy;

R^{14} is: hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkyl-$COOR^6$, and

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R^{15}; and

R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$. SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

2. The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.

3. The compound of Claim 2, wherein Z is C_1-C_6 alkyl, aryl or heteroaryl.

4. The compound of Claim 3. wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

5. The compound of Claim 4. wherein R^1 is C_3-C_6 alkyl or $(CH_2)_n$-C_3-C_6 cycloalkyl; R^2 and R^3 are each independently C_1-C_3 alkyl; and r is 1.

6. The compound Claim 5. wherein X is positioned para to Y; and R^3 is positioned ortho to Y.

7. A compound having a structural Formula II,



II

and pharmaceutically acceptable salts, solvates. hydrates or stereoisomers thereof, wherein:

Q is: $-C(O)OR^6$ or R^{6A};

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is: a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
f) heterocyclyl;
wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

m and n' are each independently: 0, 1, 2, 3 or 4;
n is: 0, 1, 2 or 3;
p is: 1 or 2;
r is: 1, 2, 3 or 4;

R^1 is: aryl,
haloalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkyl-C_1-C_6 alkoxy,
C_1-C_6 alkyl-aryl,
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{1a} and R^{1b} are each independently:

hydrogen,

C_1-C_6 alkyl, or

R^1 and R^{1a}, R^1 and R^{1b}, R^2 and R^{1a}, R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R^2 is: hydrogen,

haloalkyl,

C_1-C_6 alkyl,

C_1-C_6 alkyl-C_1-C_6 alkoxy,

C_1-C_6 alkyl-aryl,

C_2-C_6 alkenyl,

C_2-C_6 alkynyl,

$(CH_2)_n$-C_3-C_6 cycloalkyl,

C_1-C_6 alkoxy,

aryl, or

R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{2a} is: hydrogen, halo or C_1-C_6 alkyl and wherein R^2 and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R^{15};

R^3 is: hydrogen,

halo,

cyano,

haloalkyl,

C_1–C_6 alkyl,

$(CH_2)_n$-C_3-C_6 cycloalkyl,

(C_1–C_4 alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

(C_1–C_4 alkyl)-$NR^7C(O)_nR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

R^4 and R^5 are each independently:

hydrogen,

halo,

C_1-C_6 alkyl

C_1-C_6 alkoxy;

aryloxy;

$N(R^8)_2$,

SR^8 or

R^4 and R^5 together being a 3- to 8-membered ring;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, C_1-C_3 alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R^7 is: hydrogen or C_1-C_6 alkyl;

R^8 and R^9 are each independently:

hydrogen, C_1-C_6 alkyl, aryl, heteroaryl, or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl and C_1-C_6 alkoxy;

R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

8. The compound Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.

9. The compound of Claim 8, wherein Z is C_1-C_6 alkyl, aryl or heteroaryl.

10. The compound of Claim 9, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

11. The compound of Claim 10, wherein R^1 is C_3-C_6 alkyl or $(CH_2)_n$-C_3-C_6 cycloalkyl: R^2 and R^3 are each independently C_1-C_3 alkyl; and r is 1.

12. The compound Claim 11, wherein X is positioned para to Y; and R^3 is positioned ortho to Y.

13. The compound of Claim 7, wherein the compound having a structural Formula III.



III

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or C;

Y is: C or O;

Z is: aryl or a 5- to 10-membered heteroaryl,

wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from R^{15};

R^1 and R^2 are each independently: C_1-C_6 alkyl or $(CH_2)_n$-C_3-C_6 cycloalkyl; and

R^{1a} and R^{1b}, R^3, R^4 and R^5 are each independently: hydrogen or C_1-C_6 alkyl.

14. The compound of Claim 13, wherein the compound having a structural Formula IV,



IV

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1, 2, 3, 4, or 5;

R^8 and R^9 are each independently:

hydrogen, C_1-C_6 alkyl, aryl, heteroaryl, or heterocyclyl,

wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl and C_1-C_6 alkoxy: and:

R^{12} is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

15. The compound of Claim 14, wherein the compound having a structural Formula V,



V

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein R^1 and R^2 are each independently C_1-C_4 alky or $(CH_2)_n$-C_3-C_6 cycloalkyl; R^3 is C_1-C_4 alky; $(R^{12})_1$ is halo, haloalkyl, or haloalkyloxy; and $(R^{12})_2$ is F, Cl or Br.

16. The compound of Claim 15, wherein R^1 is methyl, ethyl, propyl, clcylopropyl, cycloproylmethyl, cyclobutyl: R^3 is methyl and $(R^{12})_1$ is OCF_3.

17. A compound having a structural Formula VI,



VI

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally substituted with one or more groups selected from R^{15};

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

R^1 is: hydrogen,
haloalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkyl-C_1-C_6 alkoxy,
C_1-C_6 alkyl-aryl,
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy,
aryl, or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{1a} and R^{1b} are each independently:
hydrogen,
C_1-C_6 alkyl, or
R^1 and R^{1a}, R^1 and R^{1b}, R^2 and R^{1a}, R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R^2 is: hydrogen,
haloalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkyl-C_1-C_6 alkoxy.
C_1-C_6 alkyl-aryl,
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,

$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy,
aryl, or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{2a} is: hydrogen, halo or C_1-C_6 alkyl and wherein R^2 and R^{2a} together being a 3- to 8-membered ring: and wherein alkyl being optionally substituted with one or more groups independently selected from R^{15};

R^3 is: hydrogen,
halo,
cyano,
haloalkyl,
C_1–C_6 alkyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
(C_1–C_4 alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,
(C_1–C_4 alkyl)-$NR^7C(O)_pR^9$, and
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^7 is: hydrogen or C_1-C_6 alkyl;

R^8 and R^9 are each independently:
hydrogen, C_1-C_6 alkyl, aryl, heteroaryl, or heterocyclyl, and
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano,

hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl and C_1-C_6 alkoxy; and

R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

18. The compound of Claim17, wherein the compound having a structural Formula VII,



VII

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1, 2, 3, or 4;

T is: O, NR^{1c} or S;

R^{1c} is: hydrogen or C_1-C_6 alkyl;

R^{10} and R^{11} are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, C_1-C_6 alkyl or C_1-C_6 alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from R^{15}.

19. The compound of Claim 18, wherein the compound having a structural Formula VIII,



VIII

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

R^1 is: C_3-C_5 alky or $(CH_2)_n$-C_3-C_6 cycloalkyl;

R^2 and R^3 are each independently: C_1-C_3 alkyl;

R^{10} is: halo, haloalkyl or C_1-C_3 alkyl, and

wherein R^{10} being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring: and

R^{11} is: hydrogen or C_1-C_6 alkyl.

20. The compound of Claim 19, wherein R^{10} is Cl, F, Br, CH_3 or CF_3 being substituted at a position 5 of benzothiophenyl ring.

21. A compound having a structural Formula IX,



IX

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: O, S or NR^{14};

W is:  , hydrogen, C_1-C_6 alkyl, $(CH_2)_n$-C_3-C_6 cycloalkyl, haloalkyl or acyl:

Q is: $-C(O)OR^6$ or R^{6A}:

X is: a bond, C, O, S or $S[O]_p$:

Y is: a bond, S, C or O:

Z is:
a) aliphatic group,
b) aryl,
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15}:

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

R^1 is: hydrogen,
haloalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkyl-C_1-C_6 alkoxy.

C_1-C_6 alkyl-aryl,
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy,
aryl, or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{1a} and R^{1b} are each independently:
hydrogen,
C_1-C_6 alkyl, or
R^1 and R^{1a}, R^1 and R^{1b}, R^2 and R^{1a}, R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R^2 is: hydrogen.
haloalkyl.
C_1-C_6 alkyl.
C_1-C_6 alkyl-C_1-C_6 alkoxy,
C_1-C_6 alkyl-aryl.
C_2-C_6 alkenyl,
C_2-C_6 alkynyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
C_1-C_6 alkoxy.
aryl, or
R^1 and R^2 together being a 5- to 8-membered heterocyclyl ring, and
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R^{15};

R^{2a} is: hydrogen, halo or C_1-C_6 alkyl and wherein R^2 and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R^{15};

R^3 is: hydrogen,
halo,
cyano,
haloalkyl,
C_1–C_6 alkyl,
$(CH_2)_n$-C_3-C_6 cycloalkyl,
(C_1–C_4 alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,
(C_1–C_4 alkyl)-$NR^7C(O)_pR^9$, and
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R^{15};

R^4 and R^5 are each independently:
hydrogen,
halo,
C_1-C_6 alkyl
C_1-C_6 alkoxy;
aryloxy:
$N(R^8)_2$,
SR^8 or
R^4 and R^5 together being a 3- to 8-membered ring;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl:

R^{6A} is: carboxamide. C_1-C_3 .alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R^7 is: hydrogen or C_1-C_6 alkyl;

^{8} and R^{9} are each independently:

hydrogen, C_1-C_6 alkyl, aryl, heteroaryl. or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy. oxo. C_1-C_6 alkyl and C_1-C_6 alkoxy;

R^{14} is: hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkyl-$COOR^{6}$, and

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R^{15}; and

R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^{8})_2$, $NR^{8}S(O)_2R^{9}$, $NR^{8}C(O)_pR^{9}$, $C(O)NR^{8}R^{9}$, $C(O)_pR^{8}$, SR^{8}, $S(O)_pR^{8}$ or $S(O)_2NR^{8}R^{9}$.

22. The compound of Claim 21. wherein the compound having a structural Formula X:



X

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n and q are each independently: 1, 2. 3 or 4;

T is: O. NR^{1c} or S;

X is: C, O or S;

R^{1} is: hydrogen, C_1-C_6 alkyl or $(CH_2)_n$-C_3-C_6 cycloalkyl;

R^{1a}. R^{1b}. R^{1c} and R^{2} are each independently: hydrogen or C_1-C_6 alkyl: and

R^{10} and R^{11} are each independently:

hydrogen. nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy. aryloxy,

C_1-C_6 alkyl or C_1-C_6 alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from R^{15}.

23. The compound of Claim 22. wherein the compound having a structural Formula XI:



XI

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1 or 2;

E is O, S or NR^{14};

R^1, R^2 and R^{11} are each independently: C_1-C_4 alkyl;

R^{10} is: Cl, F, Br, CH_3 or CF_3, and wherein R^{10} being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring: and

R^{14} is: hydrogen, C_1-C_6 alkyl or aryl.

24. A compound selected from the group consisting of No. 1-120 and 121:

No.	Structure	Name
1		3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
2		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-

No.	Structure	Name
		2-methyl-phenyl)-propionic acid
3		(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
4		(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
5		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
6		(4-{2-[(5-Chloro-3-ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
7		4-{2-[(6-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
8		4-{2-[(7-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
9		(4-{2-[(4-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
10		(4-{2-[(5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
11		(4-{2-[(5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
12		2-[4-(3-{[5-(4'-Fluoro-biphenyl-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-propyl)-phenoxy]-2-methyl-propionic acid
13		2-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethyl}-phenoxy)-2-methyl-propionic acid
14		2-(4-{3-[(3,5-Dimethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
15		2-(4-{3-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-

No.	Structure	Name
		propionic acid
16		2-(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid
17		2-(4-{2-[(3-Ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-3-propyl-phenoxy)-2-methyl-propionic acid
18		2-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
19		3-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid
20		[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
21		[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic

No.	Structure	Name
		acid
22		[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
23		(2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propyl-amino]-ethylsulfanyl} phenoxy)-acetic acid
24		(2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
25		(2-Methyl-4-{2-[(4-oxazol-5-yl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
26		(2-Methyl-4-{2-[propyl-(4-pyrazol-1-yl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
27		(2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid

No.	Structure	Name
28		(2-Methyl-4-{2-[propyl-(4-trifluoromethylphenylmethanesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
29		(4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
30		(4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31		[2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
32		[2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
33		[2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
34		(R)-(2-Methyl-4-{1-methyl-2-[(3-methyl-5-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-

No.	Structure	Name
		phenoxy)-acetic acid
35	 chiral	(R)-3-(4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
36	 chiral	(R)-(4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
37		(4-{2-[(4-Bromo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
38		(4-{2-[(3,4-Dichloro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
39		(4-{2-[(4-Isopropyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
40		(2-Methyl-4-{2-[(4-pentyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid

No.	Structure	Name
41		(4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
42		(2-Methyl-4-{2-[propyl-(3-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
43		(4-{2-[(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
44		(4-{2-[(3,4-Dibromo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
45		(2-Methyl-4-{2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
46		(4-{2-[(2,4-Dichloro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
47		(4-{2-[(4-Iodo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
48		(4-{2-[(3-Chloro-4-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
49		(4-{2-[(4-Bromo-2,5-difluoro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
50	chiral 	(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
51	chiral 	(4-{2-[(3,4-Dichloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
52		(2-Methyl-4-{2-[propyl-(2'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
53		(2-Methyl-4-{2-[propyl-(3'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
54		(2-Methyl-4-{2-[propyl-(4'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid

No.	Structure	Name
55		(4-{2-[(2'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
56		(4-{2-[(4'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
57		(2-Methyl-4-{2-[propyl-(4'-trifluoromethoxy-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
58		(4-{2-[(3',4'-Dichloro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
59		(4-{2-[(3'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
60		(4-{2-[(2'-Chloro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
61		(4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
62		(4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic

No.	Structure	Name
		acid
63		(4-{2-[(3'-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
64		(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
65	 chiral	(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
66	 chiral	(2-Methyl-4-{1-methyl-2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
67	 chiral	(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
68	 chiral	(4-{2-[(3-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
69		(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
70		(4-{2-[(4-Isobutyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
71		(4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
72		(4-{2-[(4-Bromo-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
73		(4-{2-[(4-Butyl-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
74		(4-{2-[(3-Chloro-4-isobutyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
75		(4-{2-[(4-Bromo-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
76		(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
77		(4-{2-[(2-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
78		(4-{2-[(3-Chloro-4-propyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
79		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-propyl-phenoxy)-acetic acid
80		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
81		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-trifluoromethyl-phenoxy)-acetic acid
82		[2-Methyl-4-(1-{[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-methyl}-propylsulfanyl)-phenoxy]-acetic acid

No.	Structure	Name
83		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
84		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
85		(2-Methyl-4-{2-[(3-methyl-5-trifluoromethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
86		(2-Methyl-4-{2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
87		(4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
88		(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
89		(2-Methyl-4-{2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
90		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
91		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
92		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
93		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclobutyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
94		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropylmethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
95		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-pentyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
96		(4-{2-[Butyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
97		(4-{2-[(Biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
98		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-2-methyl-phenylsulfanyl)-acetic acid
99		(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
100		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
101		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenyl)-propionic acid
102		2-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
103		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methoxy-phenyl)-propionic acid
104		(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
105		3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
106		(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
107		(2-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
108		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-ethyl-phenoxy)-acetic acid
109		(2-Methyl-4-{2-[(naphthalene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
110		(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
111		[3-Chloro-4-(1-{[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-methyl}-propylsulfanyl)-phenyl]-

No.	Structure	Name
		acetic acid
112	 Chiral	(R)-(3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-phenyl)-acetic acid
113		(3-Chloro-4-{2-[(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenyl)-acetic acid
114		[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid
115		3-[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid
116		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-butoxy}-2-methyl-phenyl)-propionic acid
117		[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid

No.	Structure	Name
118		[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid
119		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
120		(4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
121		[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claims 1-24 or pharmaceutically acceptable salts, solvates or hydrates thereof.

26. A pharmaceutical composition comprising (1) a compound of Claim 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof; (2) a second therapeutic agent selected from the group consisting of insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents,

HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and (3) a pharmaceutically acceptable carrier.

27. A method of modulating a peroxisome proliferator activated receptor (PPAR), comprising the step of contacting the receptor with at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

28. The method of Claim 27, wherein the PPAR is a gamma receptor.

29. The method of Claim 27, wherein the PPAR is a delta-receptor.

30. The method of Claim 27, wherein the PPAR is a gamma and delta-receptor.

31. A method for treating or preventing a PPAR-gamma mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

32. A method for treating or preventing a PPAR-delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

33. A method for treating or preventing a PPAR-gamma and delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

34. A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

35. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24.

36. A method of treating or preventing diabetes mellitus in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24.

37. A method of treating or preventing cardiovascular disease in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

38. A method of treating or preventing syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

39. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors,

statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.

40. Use of a compound of Claims 1-24 and pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for the manufacture of a medicament for the treatment of a condition modulated by a PPAR.